Bleeding, Cardiac Defect, Surgery--Complications, Fibrinogenopenia; Acquired, Transfusion-Related Acute Lung Injury, Transfusion-Associated Circulatory Overload, Congenital Heart Disease
Conditions
Keywords
bleeding, pediatric cardiac surgery, fresh frozen plasma, fibrinogen concentrate, prothrombin complex concentrate
Brief summary
In pediatric patients (newborns and infants weighing less than 10 kg) undergoing cardiac surgery with extracorporeal circulation postoperative bleeding represents a known complication with a significant impact on outcome. Fresh frozen plasma (FFP) for bleeding management is associated, particularly in this kind of patients, to volume overload and a significative increase of Transfusion Related Acute Lung Injury (TRALI), further worsening the postoperative outcome. In the adult patient FFP employment could be almost completely canceled by administration of concentrated hemostatic components - the fibrinogen concentrate and prothrombin complex concentrate (PCC). We designed this phase II pilot study to establish whether an analogous strategy, modified accordingly to pediatric physiology, could be safely and successfully applied in newborns and infants.
Detailed description
The study population will be randomized to two groups: ZEPLAST and control, respectively. The two groups will receive the same priming solution (containing Red Blood Cells and albumin 5%) and heparin/protamine management. In both groups coagulation will be assessed with rotational thromboelastometry (ROTEM - EXTEM, INTEM, HEPTEM and FIBTEM tests) after heparin antagonization. In case of bleeding, coagulopathies will be treated differently: * in the ZEPLAST group, fibrinogen deficiency (FIBTEM Maximum Clot Firmness MCF \< 8 mm) will be treated with 30 mg/kg of concentrated fibrinogen; low thrombin generation (EXTEM Clotting Time CT \> 100 s) will be treated with 20 mg/kg of prothrombin complex concentrate; * in the control group, coagulopathies will be treated with 10-20 ml/kg of FFP. In case of refractory bleeding, PCC and fibrinogen can be administered as a rescue treatment. Further ROTEM tests will be performed at 24 and 48 hours post surgery. Outcome parameters will be collected at the same timepoints.
Interventions
Treatment of acquired postoperatively fibrinogen deficiency as assessed by ROTEM FIBTEM test.
Treatment of acquired postoperatively thrombin generation deficiency as assessed by ROTEM EXTEM test.
BIOLOGICALFresh Frozen Plasma
Treatment of acquired postoperative coagulopathy as assessed by ROTEM FIBTEM and INTEM tests.
Sponsors
IRCCS Policlinico S. Donato
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
1 Days to 2 Years
Healthy volunteers
No
Inclusion criteria
* newborns and infants with weight lower than 10 kg undergoing cardiac surgery with extracorporeal circulation: * informed consent signed by both parents or legal guardian.
Exclusion criteria
* emergency surgery; * known congenital coagulopathy or suspected based on anamnesis; * participation to other clinical trials; * known hypersensitivity to components and excipients of FFP , prothrombin complex concentrate or fibrinogen concentrate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Transfusion of Fresh Frozen Plasma (FFP) | First 48 hours after surgery | Number of patients transfused with FFP |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative bleeding | First 12, 24 and 48 hours after surgery | Amount of blood collected by chest drainages |
| Severe bleeding | First 12 hours after surgery | Number of patients who experienced severe bleeding (higher than 30 ml/kg in the first 12 hours after surgery) |
| Surgical re-exploration for bleeding | First 12, 24 and 48 hours after surgery | Number of patients requiring surgical re-exploration due to bleeding (bleeding with no coagulopathies detected or refractory to pharmacological treatment) |
Countries
Italy
Outcome results
None listed